On 16th June 2025, Aayush Agrawal, acting as the Trustee of the Aayush Agrawal Trust, officially disclosed the creation of a pledge on 2,60,000 equity shares of Ajanta Pharma Limited. The pledge was created due to a change in the lender and complies with Regulation 31(1) and 31(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

This disclosure was submitted to both BSE and NSE, where Ajanta Pharma’s shares are listed under Scrip Code 532331 (BSE) and Symbol AJANTPHARM EQ (NSE). The nature of the transaction is a pledge, executed on 09th June 2025, now favoring Aditya Birla Money Ltd as the new lender.

As per the SEBI regulation, this pledge is part of the routine compliance disclosures and helps keep the investors and regulatory bodies informed about material changes in the promoter's shareholding structure. Ajanta Pharma, a prominent listed pharmaceutical company, has seen stable promoter interest, and such disclosures play a vital role in maintaining market transparency.

The 2.6 lakh pledged shares belong to the Aayush Agrawal Trust, which holds a total of 1,41,12,924 shares. With this additional pledge, the trust’s encumbered holdings rise to 55,75,002 shares, amounting to 4.67% of the company’s total share capital.

Prior to this development, Aayush Agrawal Trust had already pledged 53,15,002 shares, and with this newly added 2.6 lakh shares, the post-event pledged holding totals 55,75,002 shares, which is an increase of 0.21% of the total share capital. This level of detail is essential under SEBI SAST Regulation 31, which mandates comprehensive disclosure for creation, release, or invocation of encumbrance on promoter shares.

The promoter group of Ajanta Pharma also includes other key individuals and trusts such as Ravi P Agrawal Trust, Rajesh Agrawal Trust, Yogesh Agrawal Trust, and Gabs Investments Pvt Ltd, all of whom continue to maintain significant holdings in the company. As per the current filing, no other new pledges or releases have been recorded from these entities.

Encumbrance details included in the disclosure note the following:

• Date of Creation: 09th June 2025

• Type of Encumbrance: Pledge

• Reason: Change in lender

• Name of Lender: Aditya Birla Money Ltd

• Shares Pledged: 2,60,000

• Percentage of Share Capital: 0.21%

These shares have not been pledged for the first time in Ajanta Pharma’s history. The use of pledged shares for reasons like collateral, refinancing, or personal funding is common among promoters in India. The SEBI regulation ensures that any such moves are disclosed transparently, thereby helping investors evaluate any risks related to promoter commitments.

Despite the pledge, the overall promoter holding in Ajanta Pharma remains strong. The aggregate holding of promoters and promoter group entities is substantial, with over 70% ownership. The company's financial health, combined with consistent regulatory filings, assures market participants that such pledges are strategic in nature and not indicators of distress.

Another key aspect is the public availability of these disclosures. The document was addressed to:

• BSE Limited, Mumbai

• National Stock Exchange of India Limited, Mumbai
  And also marked to:

• The Company Secretary, Ajanta Pharma Limited

This allows shareholders and analysts to access verified information about the promoter activity, enabling informed investment decisions.

The disclosure clearly mentions that the pledge creation was executed under the purview of trust-held shares, ensuring that personal holdings and trust responsibilities remain distinctly reported. This level of compliance and documentation further strengthens investor trust in Ajanta Pharma’s promoter governance.

Ajanta Pharma’s financials and stock performance have historically demonstrated stability. However, changes in pledge status, especially when involving a new lender such as Aditya Birla Money Ltd, are significant enough to warrant market attention.

The company continues to maintain compliance with all SEBI norms, including those under SAST Regulation 31, which mandates the disclosure of:

• Total promoter shareholding

• Encumbered shareholding prior to the event

• Details of the encumbrance created

• Name of lender and the reason for encumbrance

• Post-event holding pattern

In conclusion, the pledge of 2.6 lakh shares by Aayush Agrawal Trust represents a typical financial restructuring measure involving a change in lender. It does not alter control or majority influence in Ajanta Pharma and reaffirms the promoter group’s adherence to regulatory best practices. The transaction was duly disclosed through stock exchange filings, underlining Ajanta Pharma’s continued commitment to transparent and ethical corporate governance.

With this filing, Ajanta Pharma remains fully compliant with the latest listing norms, and the market now has clarity on the status of pledged promoter shares. This will further help stakeholders in tracking future developments and promoter activities effectively.

The Upcoming IPOs in this week and coming weeks are Safe Enterprises Retail Fixtures, Globe Civil Projects, Sambhav Steel Tubes, Ellenbarrie Indutrial Gases, Kalpataru, HDB Financials, AJC Jewel, ArisInfra Solutions, Influx Healthtech, Mayasheel Ventures, Eppeltone Engineers.

The Current active IPO are Oswal Pumps, Patil Automation, Samay Projects Services, Aten Papers, Monolithisch India.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst.